| Autor: |
Rincon NL; Trinity College of Arts & Sciences, Duke University, Durham, NC, USA.; REACH Equity Summer Undergraduate Research Program (RESURP), Duke University School of Medicine, Durham, NC, USA., McDowell KR; REACH Equity Summer Undergraduate Research Program (RESURP), Duke University School of Medicine, Durham, NC, USA.; School of Nursing, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA., Weatherspoon D; Department of Dental Public Health, University of Maryland School of Dentistry, Baltimore, MD, USA., Ritchwood TD; REACH Equity Summer Undergraduate Research Program (RESURP), Duke University School of Medicine, Durham, NC, USA.; Department of Family Medicine and Community Health, Duke University School of Medicine, Durham, NC, USA., Rocke DJ; Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, USA.; Duke Cancer Institute, Duke University, Durham, NC, USA., Adjei Boakye E; Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA.; Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health System, Detroit, MI, USA., Osazuwa-Peters N; REACH Equity Summer Undergraduate Research Program (RESURP), Duke University School of Medicine, Durham, NC, USA.; Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, USA.; Duke Cancer Institute, Duke University, Durham, NC, USA.; Department of Population Health Sciences, School of Medicine, Duke University, Durham, NC, USA. |
| Abstrakt: |
In 2018, the Food and Drug Administration expanded the age of eligibility for the human papillomavirus (HPV) vaccine to 27 to 45 years. However, it is unclear if there are racial/ethnic disparities in HPV vaccine uptake for this age-group following this expanded recommendation. We aimed to identify any disparities in HPV vaccine in 27 to 45 year-olds based on sociodemographic factors. We analyzed nationally representative, cross-sectional data from the 2019 National Health Interview Survey ( n = 9440). Logistic regression models estimated the odds of vaccine uptake (receipt of ≥1 vaccine dose) based on sociodemographic factors. Participants were mostly Non-Hispanic Whites (60.7%) and females (50.9%). In adjusted models, females had over three times greater odds of vaccine uptake compared to males (aOR = 3.58; 95% CI 3.03, 4.23). Also, compared to Non-Hispanic Whites, Non-Hispanic Blacks were 36% more likely (aOR = 1.36; 95% CI 1.09, 1.70), and Hispanics were 27% less likely (aOR = 0.73; 95% CI 0.58, 0.92) to receive the vaccine. Additionally, individuals without a usual place of care had lower odds of vaccine uptake (aOR = 0.72; 95% CI 0.57, 0.93), as were those with lower educational levels (aOR high school = 0.62; 95% CI 0.50, 0.78; aOR some college = 0.83; 95% CI 0.70, 0.98). There are disparities in HPV vaccine uptake among 27 to 45 year-olds, and adult Hispanics have lower odds of receiving the vaccine. Given the vaccine's importance in cancer prevention, it is critical that these disparities are addressed and mitigated. |
